CureVac settles patent dispute litigation with Pfizer and BioNTech

CureVac and GSK have resolved their patent dispute with Pfizer and BioNTech concerning mRNA-based COVID-19 vaccines, securing a combined $740 million payment and single-digit royalties on future U.S. COVID-19 vaccine sales. As part of the settlement, CureVac grants Pfizer and BioNTech a non-exclusive license for mRNA COVID-19 and influenza products in the U.S., providing legal clarity for the major vaccine manufacturers.

Analysis

The resolution of the patent dispute between CureVac/GSK and Pfizer/BioNTech marks a significant de-risking event for all parties involved. For CureVac and its partner GSK, the settlement provides a material financial windfall, consisting of a $740 million combined payment and a future revenue stream from single-digit royalties on U.S. COVID-19 vaccine sales. This outcome validates CureVac's underlying mRNA intellectual property and provides substantial non-dilutive capital that can be redeployed into its development pipeline. For Pfizer and BioNTech, the settlement removes a significant legal overhang and quantifies a previously un-quantified liability. While they incur a financial cost, they gain crucial freedom to operate in the U.S. market through a non-exclusive license for both existing COVID-19 vaccines and future mRNA-based influenza products, securing their position in a key therapeutic area without the ongoing uncertainty and expense of litigation.

Key Decisions for Investors

• Investors in CureVac and GSK should update their valuation models to incorporate the $740 million cash infusion and the new, albeit single-digit, U.S. royalty stream.
• For those holding Pfizer and BioNTech, this settlement removes a major legal uncertainty, and the associated costs should be viewed as a manageable expense that secures future revenue from key mRNA franchises.
• The agreed-upon single-digit royalty rate could serve as a benchmark for valuing intellectual property in future mRNA-related licensing deals or disputes across the biotech sector.